Merck Experimental Oral Drug ‘Molnupiravir’ Could Reduce Risk of Death from Covid-19

PR PANGARAN – Based on the published preliminary clinical trial results, oral medication experimental Merck for Covid-19, molnupiravir can reduce about 50 percent of the chances hospitalized.

Not only that, oral medication from Merck This can also reduce the risk death for patients Covid-19 who have a serious illness.

Merck and its partner Ridgeback Biotherapeutics plan to seek US emergency use authorization for the pill Covid-19 as soon as possible and to submit applications to regulatory bodies worldwide.

Also Read: Link to Watch Love Bonds Friday October 1, 2021: Aldebaran Ready to Arrest Iqbal, Irvan Visits Sofia’s Grave

Due to the positive results, the Phase 3 trial was terminated early on the recommendation of an outside monitor.

“This will change the dialogue around how to manage Covid-19, ”Robert Davis, CEO Merck, told Reuters quoted

If allowed, molnupiravir, which is designed to insert errors into the genetic code of the virus, will be the first oral antiviral drug for Covid-19.

Also Read: The Biggest Fear of Every Zodiac: Leo is afraid of being forgotten, Libra is afraid of making the wrong decision

Rivals including Pfizer and Swiss pharmaceutical Roche Holding AG are racing to develop easy-to-use antiviral pills for Covid-19 but so far, only antibody cocktails – which must be administered intravenously – are approved to treat patients Covid-19 who are not hospitalized.



Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.